
Nasdaq:SAVA fell nearly 10% on Tuesday after rising nearly 90% earlier this week. Analysts raised their ratings after SAVA announced positive news about its Alzheimer’s clinical trial. NASDAQ:SAVA retreated Tuesday after nearly doubling in price on...